Reading LAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LAB free→Reading LAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LAB free→QuarterlyIQ Insights · LAB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Changes in Control of Registrant. To the extent required by this Item, the information included in
Unregistered Sales of Equity Securities. Certain of the shares of Standard BioTools Common Stock being issued in the Merger will be issued in private placements exempt from registration under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a)(2) of the Securities Act. Neither this Current Report on Form 8-K nor any of the exhibits attached hereto is an o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent required by this Item, the information included in
Entry into a Material Definitive Agreement. Merger Agreement On June 6, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (“Merger Sub”), pursuant to which Standard BioTools and Treeline will combine in an all-s…
Regulation FD Disclosure. On June 8, 2026, Standard BioTools and Treeline issued a joint press release announcing the execution of the Merger Agreement (the “Press Release”), and Standard BioTools included prepared remarks and an investor presentation on its website. On June 8, 2026, Standard BioTools conducted a town hall for its employees related to the Transactions. Copies of the Press Release, the prepared remarks, the investor presentation and the town hall presentation are attached as E…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 29, 2026, the Human Capital Committee of the Board of Directors of Standard BioTools Inc. (the “Company”) approved a grant of 500,000 restricted stock units for Sean Mackay, Chief Business Officer of the Company, under the Company’s 2026 Equity Incentive Plan (the “2026 Plan”), effective as of June 20, 2026 (the “RSU Award”). Subject to Mr.…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.